LUCD at a glance
Lucid Diagnostics Inc. (LUCD, SEC CIK 1799011) filed its latest 10-K annual report on March 25, 2026, a 10-Q quarterly report on August 12, 2026, an 8-K current report on September 22, 2026 and Form 4 insider filings as recently as February 24, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Lucid Diagnostics Inc. (LUCD) reported revenue of $4.7 million (up 8.3% from FY2024) and a net loss of $58.0 million. Diluted EPS was -$0.69.
- As of June 30, 2026, 22 institutional investment managers tracked by SignalX reported holding Lucid Diagnostics Inc. (LUCD) shares worth $25.7 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $4.7M
- +8.3% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 22 funds
- $25.7M · +0 vs prior quarter
- Latest 8-K
- Sep 22, 2026
- Item 7.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Q2 revenue $1.5M vs $1.2M, up $0.3M YoY, driven by EsoGuard test consideration
- Q2 gross margin 6.7% vs negative 25.0% YoY, with cost of revenue $1.4M vs $1.5M
- EsoGuard remained the sole commercial product; revenue increased $0.3M YoY
- Cash $33.4M at June 30; six-month operating cash use $23.4M and financing cash inflow $22.3M
- April offering netted $16.8M; management expects recurring losses and negative operating cash flow, requiring additional financing and reimbursement expansion
AI summary of the LUCD 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- Boilerplate Regulation FD disclaimer only; no substantive investor disclosure in the provided text
Item EX-99.1: Item EX-99.1
- CMS advisory panel recommended preserving EsoGuard’s original gapfill payment basis under CLFS for PLA code 0114U
- Final Medicare payment determination expected in November after public comment, reducing near-term reimbursement uncertainty
Item 2.02: Results of Operations and Financial Condition
- Item 2.02 references furnished information under Items 2.02 and 7.01
- No operating results or financial figures included in the provided text
Item EX-99.1: Item EX-99.1
- Q2 revenue $1.474 million, up from $1.163 million, with 2,770 EsoGuard tests processed
- Concert secured first laboratory benefit manager coverage policy, with multiple client health plans adopting it
Item 5.07: Submission of Matters to a Vote of Security Holders
- Stockholders representing approximately 84.7% of eligible shares participated, indicating strong meeting engagement
- James Cox, John Palumbo, and Ronald Sparks re-elected as Class B directors through the third succeeding annual meeting
AI summaries of LUCD 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for LUCD
Don't miss the next LUCD filing
- Alerts as it files. A push when LUCD files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut LUCD, by share count.
- Ask anything. An AI agent that reads every LUCD filing and answers with sources.
LUCD alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| MCGRATH DENNIS M | A | Feb 20, 2026 | 470,000 | - |
| Cox James L | A | Feb 20, 2026 | 123,000 | - |
| PALUMBO JOHN R | A | Feb 20, 2026 | 123,000 | - |
| White Debra | A | Feb 20, 2026 | 123,000 | - |
| Sparks Ronald M | A | Feb 20, 2026 | 123,000 | - |
| O'Neil Shaun | A | Feb 20, 2026 | 620,000 | - |
| SOKOLOV JACQUE J | A | Feb 20, 2026 | 123,000 | - |
| Aklog Lishan | A | Feb 20, 2026 | 2,170,000 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $4.3M | $4.7M |
| Operating Income | -$48.5M | -$46.1M | -$49.6M |
| Net Income | -$52.7M | -$45.5M | -$58.0M |
| Op. Margin | - | -1059.6% | -1054.8% |
| Net Margin | - | -1047.6% | -1232.7% |
| Balance Sheet | |||
| Total Assets | $27.3M | $30.7M | $40.4M |
| Equity | - | $5.4M | $10.9M |
| ROE | - | -844.5% | -530.4% |
| Per Share | |||
| EPS | $-1.26 | $-1.05 | $-0.69 |
| Cash Flow | |||
| Operating CF | - | -$44.1M | -$46.5M |
| CapEx | - | $296K | $197K |
Source: XBRL data in Lucid Diagnostics Inc. (LUCD)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate LUCD share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 22 | $25.7M |
| Q1 2026 | 22 | $17.2M |
| Q4 2025 | 19 | $15.4M |
| Q3 2025 | 16 | $12.0M |
| Q2 2025 | 16 | $12.0M |
| Q1 2025 | 12 | $3.0M |
| Q4 2024 | 5 | $592,000 |
| Q3 2024 | 3 | $35,000 |
- BlackRock+3.73M (+81%)
- Vanguard Capital Management LLC+2.40M (+58%)
- State Street Corp+882.8K (+57%)
- Wells Fargo & Co+792.7K (+62%)
- Northern Trust+549.3K (+82%)
- Renaissance Technologies LLC−428.4K (-86%)
- Goldman Sachs Group−172.0K (-71%)
- FMR LLC (Fidelity)−116.4K (-97%)
- PNC Financial Services−13 (-7%)
- Citadel Advisors LLC+36.4K
- Principal Financial Group+11.4K
- StoneX Group Inc.−14.6K
- Millennium Management−11.3K
Source: 13F-HR filings on SEC EDGAR (aggregated from 115 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
LUCD filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Sep 22, 2026 | - | Analysis | - |
| 8-K | Aug 13, 2026 | - | Analysis | - |
| 10-Q | Aug 12, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Jun 24, 2026 | - | Analysis | - |
| 8-K | May 14, 2026 | - | Analysis | |
| 10-Q | May 13, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | Apr 24, 2026 | - | Analysis | - |
| 8-K | Apr 23, 2026 | - | Analysis | - |
| 8-K | Mar 26, 2026 | - | - | - |
| 10-K | Mar 25, 2026 | Dec 31, 2025 | - | |
| 4 | Feb 24, 2026 | - | - | - |
| 4 | Feb 24, 2026 | - | - | - |
| 4 | Feb 24, 2026 | - | - | - |
| 4 | Feb 24, 2026 | - | - | - |
| 4 | Feb 24, 2026 | - | - | - |
| 4 | Feb 24, 2026 | - | - | - |
| 4 | Feb 24, 2026 | - | - | - |
| 4 | Feb 24, 2026 | - | - | - |
| 4 | Feb 24, 2026 | - | - | - |
| 10-Q | Nov 12, 2025 | Sep 30, 2025 | Analysis | |
| 10-Q | Aug 12, 2025 | Jun 30, 2025 | - | |
| 10-Q | May 13, 2025 | Mar 31, 2025 | - | |
| 10-K | Mar 24, 2025 | Dec 31, 2024 | - | |
| 10-Q | Nov 12, 2024 | Sep 30, 2024 | - | |
| 10-Q | Aug 12, 2024 | Jun 30, 2024 | - |
Related Health Care companies
- ARAY · ACCURAY INCSurgical & Medical Instruments & Apparatus
- ATEC · Alphatec Holdings, Inc.Surgical & Medical Instruments & Apparatus
- ANGO · ANGIODYNAMICS INCSurgical & Medical Instruments & Apparatus
- ANIK · Anika Therapeutics, Inc.Surgical & Medical Instruments & Apparatus
- AORT · ARTIVION, INC.Surgical & Medical Instruments & Apparatus
- ATRC · AtriCure, Inc.Surgical & Medical Instruments & Apparatus
- RCEL · AVITA Medical, Inc.Surgical & Medical Instruments & Apparatus
- BAX · Baxter InternationalSurgical & Medical Instruments & Apparatus
LUCD SEC filings: frequently asked questions
Which institutions hold LUCD stock?
As of June 30, 2026, the largest Lucid Diagnostics Inc. (LUCD) holders among the 13F filers tracked by SignalX were BlackRock ($9.0 million), Vanguard Capital Management LLC ($7.0 million), State Street Corp ($2.6 million), Wells Fargo & Co ($2.2 million), Northern Trust ($1.3 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was LUCD's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Lucid Diagnostics Inc. (LUCD) reported revenue of $4.7 million (up 8.3% from FY2024) and a net loss of $58.0 million. Diluted EPS was -$0.69. The figures come from the XBRL data in the 10-K.
What did LUCD report in its latest 8-K?
Lucid Diagnostics Inc. (LUCD) filed an 8-K on September 22, 2026 reporting Item 7.01 (Regulation FD Disclosure). Boilerplate Regulation FD disclaimer only; no substantive investor disclosure in the provided text.
What are the latest LUCD SEC filings?
Lucid Diagnostics Inc. (LUCD) filed its latest 10-K annual report on March 25, 2026, a 10-Q quarterly report on August 12, 2026, an 8-K current report on September 22, 2026 and a Form 4 insider filing on February 24, 2026.
What is LUCD's SEC CIK number?
Lucid Diagnostics Inc. (LUCD)'s SEC Central Index Key (CIK) is 1799011. EDGAR lists every LUCD filing under that number.
Ask anything about LUCD
The research agent reads LUCD's filings, financials, insider trades and 13F holders, then answers with sources.